HRP20171153T1 - Protutijela protiv csf-1r - Google Patents
Protutijela protiv csf-1r Download PDFInfo
- Publication number
- HRP20171153T1 HRP20171153T1 HRP20171153TT HRP20171153T HRP20171153T1 HR P20171153 T1 HRP20171153 T1 HR P20171153T1 HR P20171153T T HRP20171153T T HR P20171153TT HR P20171153 T HRP20171153 T HR P20171153T HR P20171153 T1 HRP20171153 T1 HR P20171153T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- antibody
- csf
- seq
- intended
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 5
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 210000002381 plasma Anatomy 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 2
- 238000011394 anticancer treatment Methods 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 238000011269 treatment regimen Methods 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 229940022353 herceptin Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (16)
1. Protutijelo koje se specifično veže na varijantu ljudskog CSF-1R (SEQ ID NO. 15), naznačeno time što sadrži teški lanac koji sadrži aminokiselinski slijed sa SEQ ID NO:9 i laki lanac koji sadrži aminokiselinski slijed sa SEQ ID NO:10.
2. Protutijelo koje se specifično veže na ljudski CSF-1R (SEQ ID NO. 16), naznačeno time što sadrži teški lanac koji sadrži aminokiselinski slijed sa SEQ ID NO:9 i laki lanac koji sadrži aminokiselinski slijed sa SEQ ID NO:10.
3. Protutijelo u skladu s patentnim zahtjevima 1-4 ili 2, naznačeno time što sadrži dva teška lanca, od kojih svaki sadrži aminokiselinski slijed sa SEQ ID NO:9. i dva laka lanca, od kojih svaki sadrži aminokiselinski slijed sa SEQ ID NO:10.
4. Farmaceutski pripravak, naznačen time što sadrži protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, kao i farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćnu tvar.
5. Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time što dodatno sadrži dodatno farmaceutsko sredstvo.
6. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeno time što je namijenjeno upotrebi kao medikament.
7. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeno time što je namijenjeno upotrebi u liječenju raka.
8. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 7, naznačeno time što je rak leukemija, rak dojke, rak endometrija, rak prostate, rak jajnika, kolorektalni rak, hepatocelularni rak, rak bubrega, multipli mielom ili Hodgkinov limfom.
9. Protutijelo je namijenjeno upotrebi u skladu s patentnim zahtjevom 8, naznačeno time što je rak leukemija, rak dojke, rak endometrija ili rak prostate.
10. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 9, naznačeno time što je rak leukemija, rak dojke ili rak prostate.
11. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevima 6-10, naznačeno time što se protutijelo primijenjuje prije, za vrijeme, uglavnom istodobno s ili nakon početka terapije drugim antikanceroznim liječenjem.
12. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 11, naznačeno time što se navedeno antikancerozno liječenje bira iz skupine koju čine antiangiogenetsko sredstvo, kemoterapijsko sredstvo i antineoplastično sredstvo.
13. Protutijelo, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačeno time što se navedeno antineoplastično sredstvo bira iz skupine koju čine docetaksel, paklitaksel, Herceptin® i doksorubicin.
14. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeno time što je namijenjeno upotrebi u liječenju raka kod pacijenta koja se sastoji u mjerenju razine CSF-1 u uzorku uzetom iz pacijenta, gdje se uzorak bira iz skupine koju čine krv, serum, plazma, tumorske stanice i tumorske stanice u cirkulaciji, i te u primjeni na pacijentu protutijela u skladu s bilo kojim od patentnih zahtjeva 1-3 ako su razine CSF-1 više od razina CSF-1 nađenih kod kontrolne populacije.
15. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeno time što je namijenjeno upotrebi u liječenju raka kod pacijenta koja se sastoji u mjerenju razine IL-34 u uzorku uzetom iz pacijenta, gdje se uzorak bira iz skupine koju čine krv, serum, plazma, tumorske stanice i tumorske stanice u cirkulaciji, te u primjeni na pacijentu protutijela u skladu s bilo kojim od patentnih zahtjeva 1-3 ako su razine IL-34 više od razina IL-34 nađenih kod kontrolne populacije.
16. Postupak određivanja je li subjekt koji ima rak kandidat za režim liječenja raka na bazi protutijela protiv CSF-1R, gdje je navedeno protutijelo protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što se sastoji u:
određivanju razine CSF-1 ili IL-34, ili oba, ex vivo ili in vitro u uzorku iz subjekta, gdje se uzorak bira iz skupine koju čine krv, serum, plazma, tumorske stanice i tumorske stanice u cirkulaciji, gdje porast razine CSF-1, ili IL-34, ili oba, u usporedbi s razinom CSF-1, ili IL-34, ili oba, kod pojedinca koji ne boluje od raka, ukazuje da je subjekt kandidat za režim liječenja raka na bazi protutijela protiv CSF-1R.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31989610P | 2010-04-01 | 2010-04-01 | |
| EP11713416.3A EP2552966B1 (en) | 2010-04-01 | 2011-03-28 | Antibodies against csf-1r |
| PCT/US2011/030148 WO2011123381A1 (en) | 2010-04-01 | 2011-03-28 | Antibodies against csf-1r |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171153T1 true HRP20171153T1 (hr) | 2017-10-06 |
Family
ID=44010222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171153TT HRP20171153T1 (hr) | 2010-04-01 | 2017-07-27 | Protutijela protiv csf-1r |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8263079B2 (hr) |
| EP (2) | EP3156419A1 (hr) |
| JP (1) | JP5767310B2 (hr) |
| KR (1) | KR101439719B1 (hr) |
| CN (1) | CN102834414B (hr) |
| AR (1) | AR080698A1 (hr) |
| AU (1) | AU2011232850B2 (hr) |
| BR (1) | BR112012024564A2 (hr) |
| CA (1) | CA2795081C (hr) |
| CY (1) | CY1119324T1 (hr) |
| DK (1) | DK2552966T3 (hr) |
| EA (1) | EA021600B1 (hr) |
| ES (1) | ES2640909T3 (hr) |
| HR (1) | HRP20171153T1 (hr) |
| HU (1) | HUE036379T2 (hr) |
| IL (1) | IL222222A (hr) |
| JO (1) | JO3291B1 (hr) |
| LT (1) | LT2552966T (hr) |
| ME (1) | ME02806B (hr) |
| MX (1) | MX2012011234A (hr) |
| NZ (1) | NZ602621A (hr) |
| PL (1) | PL2552966T3 (hr) |
| PT (1) | PT2552966T (hr) |
| RS (1) | RS56219B1 (hr) |
| SG (1) | SG183829A1 (hr) |
| SI (1) | SI2552966T1 (hr) |
| TW (1) | TWI402078B (hr) |
| UA (1) | UA111818C2 (hr) |
| WO (1) | WO2011123381A1 (hr) |
| ZA (1) | ZA201206926B (hr) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011070024A1 (en) | 2009-12-10 | 2011-06-16 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
| US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| WO2017120461A1 (en) | 2016-01-08 | 2017-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| KR101656548B1 (ko) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도 |
| KR101647871B1 (ko) | 2010-03-05 | 2016-08-11 | 에프. 호프만-라 로슈 아게 | 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도 |
| BR112012027994B1 (pt) | 2010-05-04 | 2021-10-13 | Five Prime Therapeutics, Inc | Anticorpo, composição farmacêutica e uso de um anticorpo |
| US9161968B2 (en) * | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| CN104159921B (zh) * | 2011-12-15 | 2018-05-04 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| CN104093740B (zh) * | 2012-02-06 | 2018-01-09 | 弗·哈夫曼-拉罗切有限公司 | 使用csf1r抑制剂的组合物和方法 |
| AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| AR097584A1 (es) * | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
| AU2014364182B2 (en) | 2013-12-09 | 2019-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
| KR102000224B1 (ko) * | 2014-02-03 | 2019-07-16 | 전대연 | 스마트 이메일 관리방법 |
| KR20230086809A (ko) | 2014-06-23 | 2023-06-15 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법 |
| WO2016069727A1 (en) | 2014-10-29 | 2016-05-06 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| SG11201704792UA (en) | 2014-12-22 | 2017-07-28 | Five Prime Therapeutics Inc | Anti-csf1r antibodies for treating pvns |
| CN107709365A (zh) | 2015-04-13 | 2018-02-16 | 戊瑞治疗有限公司 | 癌症组合疗法 |
| WO2016189045A1 (en) | 2015-05-27 | 2016-12-01 | Ucb Biopharma Sprl | Method for the treatment of neurological disease |
| EA201890020A1 (ru) | 2015-06-15 | 2018-05-31 | Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити | Способы и композиции для лечения ассоциированных со старением состояний |
| JP6621252B2 (ja) * | 2015-06-17 | 2019-12-18 | 国立大学法人北海道大学 | 治療耐性がんに対する治療耐性低減剤 |
| EP3108897A1 (en) | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| US20180222985A1 (en) * | 2015-06-24 | 2018-08-09 | Hoffmann-La Roche Inc. | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| CN108367070B (zh) * | 2015-11-04 | 2022-10-28 | 杜克大学 | 免疫毒素与检查点抑制剂的组合治疗 |
| WO2017085566A1 (en) * | 2015-11-20 | 2017-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for increase/induction of immune responses |
| WO2017091429A1 (en) | 2015-11-24 | 2017-06-01 | Eli Lilly And Company | Combination therapy for cancer |
| MA44309A (fr) * | 2015-11-25 | 2018-10-03 | Nogra Pharma Ltd | Oligonucléotides antisens il-34 et leurs procédés d'utilisation |
| ES2975517T3 (es) | 2016-04-28 | 2024-07-08 | Alkahest Inc | Fracciones de plasma como terapia para el cáncer de timo |
| EP3471753A1 (en) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| EP3504239B1 (en) | 2016-08-25 | 2024-05-29 | F. Hoffmann-La Roche AG | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
| TW201825519A (zh) | 2016-10-18 | 2018-07-16 | 美商美國禮來大藥廠 | TGFβ受體II抗體 |
| EA039316B1 (ru) | 2016-10-24 | 2022-01-12 | Алкахест, Инк. | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением |
| EP3558360A1 (en) * | 2016-12-22 | 2019-10-30 | F. Hoffmann-La Roche AG | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| WO2018144334A1 (en) | 2017-02-02 | 2018-08-09 | Imclone Llc | Dosing regimen for anti-csf-1r antibody |
| WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
| JP2020517256A (ja) | 2017-04-19 | 2020-06-18 | エルスター セラピューティクス， インコーポレイテッド | 多重特異性分子およびその使用 |
| DK3615057T3 (da) | 2017-04-26 | 2024-01-02 | Alkahest Inc | Doseringsskema til behandling af kognitive svækkelser med blodplasmaprodukter |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| WO2018213665A1 (en) | 2017-05-19 | 2018-11-22 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| UA128472C2 (uk) | 2017-08-25 | 2024-07-24 | Файв Прайм Терапеутікс Інк. | B7-h4 антитіла і методи їх використання |
| JP2020535119A (ja) | 2017-09-13 | 2020-12-03 | ファイヴ プライム セラピューティクス インク | 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ−１抗体組合せ併用療法 |
| EP3720881A1 (en) | 2017-12-08 | 2020-10-14 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| GB201803226D0 (en) | 2018-02-28 | 2018-04-11 | Ultrahuman Twelve Ltd | CSF1R Binding agents |
| KR20200144094A (ko) | 2018-03-02 | 2020-12-28 | 파이브 프라임 테라퓨틱스, 인크. | B7-h4 항체 및 이의 사용 방법 |
| CN112154153A (zh) * | 2018-03-28 | 2020-12-29 | 百时美施贵宝公司 | 白介素-2/白介素-2受体α融合蛋白以及使用方法 |
| CN109096397B (zh) * | 2018-07-18 | 2019-04-16 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及应用 |
| CN108948201B (zh) * | 2018-07-18 | 2019-05-07 | 博奥信生物技术（南京）有限公司 | 抗人csf-1r单克隆抗体及应用 |
| CN108948200B (zh) * | 2018-07-18 | 2019-05-10 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及其应用 |
| EA202190183A1 (ru) * | 2018-07-27 | 2021-05-18 | Алектор Ллс | Антитела к siglec-5 и способы их применения |
| US20220242957A1 (en) | 2018-09-27 | 2022-08-04 | Marengo Therapeutics, Inc. | Csf1r/ccr2 multispecific antibodies |
| JP7504090B2 (ja) | 2018-10-26 | 2024-06-21 | アルカヘスト，インコーポレイテッド | 疼痛、創傷治癒及び術後回復の改善のための血漿及び血漿画分の使用 |
| TWI733274B (zh) | 2018-12-13 | 2021-07-11 | 財團法人生物技術開發中心 | 抗人類csf-1r抗體及其用途 |
| EP3935391B1 (en) * | 2019-03-05 | 2024-04-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Biomarkers for renal cell carcinoma |
| WO2020232051A1 (en) * | 2019-05-15 | 2020-11-19 | Biosion Inc. | Antibody binding csf-1r and use thereof |
| EP3976104A4 (en) * | 2019-05-24 | 2023-10-04 | Elixiron Immunotherapeutics (Hong Kong) Limited | ANTI-CSF1R ANTIBODIES, IL10 FUSION PROTEINS AND THEIR USES |
| CN110499295A (zh) * | 2019-09-11 | 2019-11-26 | 宝船生物医药科技(上海)有限公司 | 一种csf-1r报告基因细胞株及其制备方法和应用 |
| JP2022550069A (ja) | 2019-09-26 | 2022-11-30 | エフ．ホフマン－ラ ロシュ アーゲー | 抗ｃｓｆ－１ｒ抗体 |
| KR102373965B1 (ko) * | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
| CN115806626B (zh) * | 2022-06-21 | 2024-02-23 | 四川大学华西医院 | 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| ES2070172T3 (es) | 1988-04-16 | 1995-06-01 | Celltech Ltd | Procedimiento para producir proteinas mediante adn recombinante. |
| JPH0967400A (ja) | 1995-08-31 | 1997-03-11 | Toray Ind Inc | モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用 |
| DK1572106T3 (da) | 2002-11-15 | 2010-08-23 | Novartis Vaccines & Diagnostic | Fremgangsmåde til forebyggelse og behandling af cancermetastase og knogletab forbundet med cancermetastase |
| NZ561137A (en) | 2005-03-08 | 2011-09-30 | Pharmacia & Upjohn Co Llc | Stable anti-CTLA-4 antibody compositions with chelating agents |
| TWI595005B (zh) * | 2007-08-21 | 2017-08-11 | 安健股份有限公司 | 人類ｃ－ｆｍｓ抗原結合蛋白質 |
| RU2547586C2 (ru) * | 2008-03-14 | 2015-04-10 | Трансжене С.А. | Антитело против csf-1r |
-
2011
- 2011-03-21 AR ARP110100905A patent/AR080698A1/es unknown
- 2011-03-22 JO JOP/2011/0097A patent/JO3291B1/ar active
- 2011-03-25 TW TW100110442A patent/TWI402078B/zh not_active IP Right Cessation
- 2011-03-28 JP JP2013502691A patent/JP5767310B2/ja not_active Expired - Fee Related
- 2011-03-28 BR BR112012024564A patent/BR112012024564A2/pt not_active Application Discontinuation
- 2011-03-28 LT LTEP11713416.3T patent/LT2552966T/lt unknown
- 2011-03-28 NZ NZ602621A patent/NZ602621A/en not_active IP Right Cessation
- 2011-03-28 CA CA2795081A patent/CA2795081C/en not_active Expired - Fee Related
- 2011-03-28 UA UAA201210763A patent/UA111818C2/uk unknown
- 2011-03-28 HU HUE11713416A patent/HUE036379T2/hu unknown
- 2011-03-28 PT PT117134163T patent/PT2552966T/pt unknown
- 2011-03-28 WO PCT/US2011/030148 patent/WO2011123381A1/en active Application Filing
- 2011-03-28 DK DK11713416.3T patent/DK2552966T3/en active
- 2011-03-28 PL PL11713416T patent/PL2552966T3/pl unknown
- 2011-03-28 RS RS20170817A patent/RS56219B1/sr unknown
- 2011-03-28 EP EP16196811.0A patent/EP3156419A1/en not_active Withdrawn
- 2011-03-28 SI SI201131235T patent/SI2552966T1/sl unknown
- 2011-03-28 EA EA201270732A patent/EA021600B1/ru not_active IP Right Cessation
- 2011-03-28 AU AU2011232850A patent/AU2011232850B2/en not_active Ceased
- 2011-03-28 KR KR1020127025707A patent/KR101439719B1/ko active IP Right Grant
- 2011-03-28 SG SG2012064135A patent/SG183829A1/en unknown
- 2011-03-28 US US13/073,004 patent/US8263079B2/en not_active Expired - Fee Related
- 2011-03-28 ME MEP-2017-174A patent/ME02806B/me unknown
- 2011-03-28 MX MX2012011234A patent/MX2012011234A/es active IP Right Grant
- 2011-03-28 EP EP11713416.3A patent/EP2552966B1/en active Active
- 2011-03-28 CN CN201180017294.3A patent/CN102834414B/zh not_active Expired - Fee Related
- 2011-03-28 ES ES11713416.3T patent/ES2640909T3/es active Active
-
2012
- 2012-09-14 ZA ZA2012/06926A patent/ZA201206926B/en unknown
- 2012-09-27 IL IL222222A patent/IL222222A/en not_active IP Right Cessation
-
2017
- 2017-07-27 HR HRP20171153TT patent/HRP20171153T1/hr unknown
- 2017-09-07 CY CY20171100949T patent/CY1119324T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171153T1 (hr) | Protutijela protiv csf-1r | |
| Lin et al. | Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential | |
| JP2013529183A5 (hr) | ||
| Singh et al. | TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy | |
| Zhang et al. | Near-infrared light irradiation induced mild hyperthermia enhances glutathione depletion and DNA interstrand cross-link formation for efficient chemotherapy | |
| HRP20211125T1 (hr) | Konjugati protutijelo-lijek koji se temelje na eribulinu i postupci uporabe | |
| JP2017514143A5 (hr) | ||
| JP2020182492A5 (hr) | ||
| Guion-Dusserre et al. | FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma | |
| RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения | |
| JP2019534034A5 (hr) | ||
| Caffo et al. | Innovative therapeutic strategies in the treatment of brain metastases | |
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| JP2014530215A5 (hr) | ||
| RU2014138420A (ru) | Антитела против sez6 и способы их применения | |
| JP2015535828A5 (hr) | ||
| JP2020508317A5 (hr) | ||
| JP2008507536A5 (hr) | ||
| JP2011157397A5 (hr) | ||
| JP2016520082A5 (hr) | ||
| JP2012523417A5 (hr) | ||
| TW202019957A (zh) | TGFβ1抑制劑及其用途 | |
| Van Wynsberghe et al. | Nephrotoxicity of anti-angiogenic therapies | |
| JP2013511288A5 (hr) | ||
| RU2013138177A (ru) | Антитела, действующие селективно на клетки с повышенной плотностью мишени рецептор эпидермального фактора роста (egfr) |